Document:

EXHIBIT
A

FORM
OF CONVERTIBLE PROMISSORY NOTE

THIS
NOTE HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION
OF THE UNITED STATES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER
SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH
ACT AND SUCH LAWS

CLINIGENCE
HOLDINGS, INC.

CONVERTIBLE
PROMISSORY NOTE

$_____________________November
19, 2019

FOR
VALUE RECEIVED, the undersigned, CLINIGENCE HOLDINGS, INC., a Delaware corporation (the “Company”), promises to pay
to the order of _______________________________________ or its registered assigns (the “Holder”), the principal sum
of ________________ Dollars ($__________________), with interest from the date hereof at the rate of 10% per annum on the unpaid
balance hereof until paid. Notwithstanding anything to the contrary in this Note, following the effective date of the Merger (as
defined in Section 4), all references to the Company in this Note shall mean Parent (as defined in Section 4), to the extent applicable.

1.                 
Principal. If not earlier converted pursuant to Section 4 hereof, the outstanding principal of this Note and all accrued
but unpaid interest shall be payable on October 31, 2020 (the “Maturity Date”).

2.                 
Interest. Subject to Section 10, the Note will bear simple interest at a rate of 10% per year. Interest (including additional
interest, if any) will be paid quarterly in arrears commencing on December 31, 2019.

Interest
will be paid to the person in whose name a note is registered at the close of business on the date that is ten days prior to the
applicable interest payment date (whether or not the day is a business day), immediately preceding the relevant interest payment
date. Interest on this Note will be computed on a 360-day year comprised of twelve 30-day months and will accrue from the date
of the original issuance of this Note. If any interest payment date falls on a date that is not a business day, such payment of
interest (or principal in the case of the Maturity Date or any earlier repurchase date for this Note) will be made on the next
succeeding business day, and no interest or other amount will be paid as a result of any such delay. For purposes herein, an “Event
of Default” exists if the Company fails to make a payment required by Section 1 or 2 hereof, and such failure is not
cured within 10 days following written notice from the Holder.

    	 	1	 

     

    

 

3.                 
Issuance of Warrants. Concurrently with the issuance of this Note, the Company shall issue to the Holder a warrant to purchase
up to ___________________ (__________) [Enter amount providing for 50% coverage] shares (the “Warrants”) of
the Company’s common stock, par value $0.00001 per share (“Common Stock”), substantially in the form attached
hereto as Exhibit B. The exercise price of the Warrants shall be One Dollar and 25/100 Cents ($1.25) per share, subject to
adjustment for stock splits, stock dividends, reclassifications and other similar recapitalization transactions that occur after
the date of issuance of the Warrants. Following the effective time of the Merger, the Warrants shall be subject to Section 3.3(b)
of the Merger Agreement.

4.                 
Conversion Events and Mechanics of Conversion.

(a.)            
Certain Definitions. For purposes of this Note, the following terms have the meanings specified below:

(i)                
“Conversion Price” means, prior to the effective time of the Merger, One Dollar and 25/100 Cents ($1.25) and, after
the effective time of the Merger, the amount equal to the quotient obtained by dividing (A) One Dollar and 25/100 Cents ($1.25)
by (B) the Exchange Ratio, in each case subject to adjustment for stock splits, stock dividends, reclassifications and other
similar recapitalization transactions that occur after the date of this Note.

(ii)             
“Conversion Shares” means, prior to the effective time of the Merger, shares of Common Stock and, after the effective
time of the Merger, shares of common stock of Parent.

(iii)           
“Exchange Ratio” has the meaning ascribed to such term in the Merger Agreement.

(iv)            
“Merger” means the merger of Merger Sub with and into the Company pursuant to the Merger Agreement, following which
the Company will be a wholly owned subsidiary of Parent.

(v)              
“Merger Agreement” means that certain Agreement and Plan of Merger, dated as of August 8, 2019, by and among the Company,
Parent, HealthDatix, Inc. (“Merger Sub”) and John Salerno.

(vi)            
“Parent” means iGambit, Inc., a Delaware corporation.

(b.)            
Conversion. If this Note has not previously been repaid in full, then the Holder shall have the option to convert all or
any portion of the unpaid principal and interest outstanding under this Note into Conversion Shares at the Conversion Price.

(c.)            
Mechanics of Conversion. The Holder shall provide written notice to the Company of its conversion of all or any part of
this Note in the form of notice attached hereto as Exhibit A. The Company shall not be obligated to issue certificates evidencing
the Conversion Shares issuable upon the conversion of this Note unless this Note is either delivered to the Company, duly endorsed,
at the office of the Company, or the Holder notifies the Company that this Note has been lost, stolen or destroyed and executes
an agreement satisfactory to the Company to indemnify the Company from any loss incurred by it in connection with this Note. After
delivery of this Note, or delivery of an agreement and indemnification in the case of a lost Note, the Company shall issue and
deliver to the Holder a certificate or certificates for the Conversion Shares, and a check payable to the Holder in the amount
equal to the cash amounts payable as a result of a conversion into fractional shares of such Common Stock. Any conversion of this
Note shall be deemed to have occurred immediately prior to the close of business on the date of such conversion, and the Holder
entitled to receive the Conversion Shares shall be treated for all purposes as the record holder of such Conversion Shares on
such date.

    	 	2	 

     

    

 

(d.)            
Fractional Shares. No fractional Conversion Shares shall be issued upon conversion of this Note. In lieu of any fractional
shares to which the Holder would otherwise be entitled, the Company shall pay cash equal to such fraction multiplied by the Conversion
Price.

5.                 
Prepayment. This Note may not be prepaid, in whole or in part, before the Maturity Date other than by and through a conversion
pursuant to Section 4.

6.                 
Transfer Restrictions. The Holder shall not transfer this Note or the Conversion Shares until (a) it has first given written
notice to the Company, describing briefly the manner of any such proposed transfer; and (b)(i) the Company, at its own expense,
has received from counsel satisfactory to the Company an opinion that such transfer can be made without compliance with the registration
requirements of the Securities Act of 1933, as amended (the “1933 Act”), and applicable state securities laws, or
(ii) a registration statement filed by the Company under the 1933 Act and applicable state securities laws is declared effective
by the Securities and Exchange Commission and state securities commissions having jurisdiction. In connection with any such sale
or transfer, the Company will if necessary promptly obtain, at its own expense, an opinion of its counsel to the effect that the
Conversion Shares may be registered without legend or restriction for sale or transfer under an exemption from such registration.
If the Rule 144 exemption is not available, public sale without registration will require compliance with an exemption under the
1933 Act. The Company shall instruct its transfer agent to accept any such opinion(s) and will process the sale or transfer within
ten business days at the Company’s expense. If either the Company or its transfer agent, individually or jointly, fails
or refuses without cause or reason to register on its books the sale or transfer of the Conversion Shares within 20 business days
after receipt of the written request to do so, the Company shall pay a penalty to the Holder in an amount of additional restricted
shares in the amount of l% of the restricted shares in the original written request for each day after the date of receipt of
the written request until the Holder receives the unrestricted shares, provided that the Holder has promptly provided all information
and certificates requested by the Company or its transfer agent.

7.                 
Currency; Payments. All references herein to “dollars” or”$” are to U.S. dollars, and all payments
of principal of, and interest on, this Note shall be made in lawful money of the United States of America in immediately available
funds. If the date on which any such payment is required to be made pursuant to the provisions of this Note occurs on a Saturday
or Sunday or legal holiday observed in the State of California, such payments shall be due and payable on the immediately succeeding
date which is not a Saturday or Sunday or legal holiday so observed.

    	 	3	 

     

    

 

8.                 
Representations and Warranties of Holder. The Holder hereby represents and warrants that:

(a.)            
Securities Not Registered. The Holder is acquiring this Note, the Conversion Shares and the Warrants (collectively, the
“Securities”) for its own account, not as an agent or nominee, and not with a view to, or for sale in connection with,
any distribution thereof in violation of applicable securities laws. By executing this Note, the Holder further represents that
Holder does not have any present contract, undertaking, understanding or arrangement with any person to sell, transfer or grant
participations to such persons or any third person, with respect to any of the Securities.

(b.)            
Access to Information. The Company has made available to the Holder the opportunity to ask questions of and to receive
answers from the Company’s officers, directors and other authorized representatives concerning the Company and its business
and prospects, and Holder has been permitted to have access to all information which it has requested in order to evaluate the
merits and risks of the purchase of this Note and the issuance of the other Securities.

(c.)            
Investment Experience. The Holder, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in this Note and the issuance of the other Securities, and has so evaluated the merits and risks of such investment. The Holder
is able to bear the economic risk of an investment in this Note and the issuance of the other Securities, and, at the present
time, is able to afford a complete loss of such investment.

(d.)            
Regulation D. The Holder is an “accredited investor” as defined in Rule 501 under the 1933 Act. In the
normal course of business, the Holder invests in or purchases securities similar to the Securities and has such knowledge and
experience in financial and business matters as to be capable of evaluating the merits and risks of purchasing this Note and the
issuance of the other Securities.

(e.)            
Securities are Unregistered. The Holder has been advised that (i) none of the Securities have been registered under the
1933 Act or other applicable securities laws, (ii) the Securities may need to be held indefinitely, (iii) the Holder will continue
to bear the economic risk of the investment in the Securities after they are subsequently registered under the 1933 Act or an
exemption from such registration is available, and (iv) when and if the Securities may be disposed of without registration in
reliance on Rule 144 promulgated under the 1933 Act, such disposition may be made only in amounts in accordance with the terms
and conditions of such Rule in effect at that time.

(f.)             
Pre-Existing Relationship, Financial Experience. The Holder has either a pre-existing personal or business relationship
with the Company or any of its officers, directors or controlling persons, or by his/its business or financial experience or the
business or financial experience of his/its financial advisors who are unaffiliated with and who are not compensated by the Company,
directly or indirectly, could be reasonably assumed to have the capacity to protect his/its own interest in connection with the
acquisition of this Note and the issuance of the other Securities.

    	 	4	 

     

    

 

(g.)            
No Advertisement. The Holder acknowledges that the offer and sale of this Note or the other Securities was not accomplished
by the publication of any advertisement.

(h.)            
No Review. The Holder understands that no arbitration board or panel, court or federal, state, municipal or other governmental
department, commission, board, bureau, agency or instrumentality, domestic or foreign, has passed upon or made any recommendation
or endorsement of the common stock into which it converts.

(i.)              
Legal Representation. The Holder has had the opportunity to confer with legal counsel of its choosing regarding the issuance
of this Note, any other Securities and any related transactions.

(j.)              
Legend. The Holder understands that the Conversion Shares shall bear a restrictive legend in substantially the following
form:

THESE
SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED
STATES. THE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED OR SOLD IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR
THE SECURITIES UNDER APPLICABLE SECURITIES LAWS UNLESS OFFERED, SOLD OR TRANSFERRED UNDER AN AVAILABLE EXEMPTION FROM THE REGISTRATION
REQUIREMENTS OF THOSE LAWS.

9.                 
Survival of Representation and Warranties. All representations and warranties made by the Holder shall survive the Maturity
Date, and shall remain effective and enforceable until the date on which claims based thereon shall have been barred by the applicable
statutes of limitation.

10.             
Default Rate. If the Company fails to pay the outstanding principal amount and all accrued interest under this Note within
30 days after the Maturity Date, the interest rate payable on this Note shall be adjusted to 15% per annum.

11.             
Usury Savings Clause. The Company and the Holder intend to comply at all times with applicable usury laws. If at any time
such laws would render usurious any amounts due under this Note under applicable law, then it is the Company’s and the Holder’s
express intention that the Company not be required to pay interest on this Note at a rate in excess of the maximum lawful rate,
that the provisions of this Section 11 shall control over all other provisions of this Note which may be in apparent conflict
hereunder, that such excess amount shall be immediately credited to the principal balance of this Note (or, if this Note has been
fully paid, refunded by the Holder to the Company), and the provisions hereof shall be immediately reformed and the amounts thereafter
decreased, so as to comply with the then applicable usury law, but so as to permit the recovery of the fullest amount otherwise
due under this Note. Any such crediting or refund shall not cure or waive any default by the Company under this Note. To the extent
applicable, Holder and the Company are relying on an exemption from applicable usury laws pursuant to Section 25118 of the California
Corporations Code. In furtherance thereof, the Holder and the Company each acknowledge and agree that, by reason of its or his
own business and financial experience or that of its or his professional advisers, it or he could reasonably be assumed to have
the capacity to protect its or his own interests in connection with the transactions contemplated by this Note.

    	 	5	 

     

    

 

12.             
Waiver. The Company expressly waives presentment, protest, demand, notice of dishonor, notice of nonpayment, notice of
maturity, notice of protest, presentment for the purpose of accelerating maturity, and diligence in collection.

13.             
Attorneys’ Fees and Costs. In the event of any legal proceedings in connection with this Note, all expenses in connection
with such legal proceedings of the prevailing party, the non-prevailing party upon demand shall reimburse including reasonable
legal fees and applicable costs and expenses. This provision shall not merge with any enforcement order or judgment on this Note
and shall be applicable to any proceeding to enforce or appeal any judgment relating to this Note.

14.             
Severability. If any one or more of the provisions contained herein, or the application thereof in any circumstance, is
held invalid, illegal or unenforceable in any respect for any reason, the validity, legality and enforceability of any such provisions
hereof shall not be in any way impaired, unless the provisions held invalid, illegal or unenforceable shall substantially impair
the benefits of the remaining provisions hereof.

15.             
Successors and Assigns. This Note shall inure to the benefit of the Holder and its successors and permitted assigns and
shall be binding upon the undersigned and its successors and permitted assigns. As used herein, the term “Holder”
shall mean and include the successors and permitted assigns of the Holder.

16.             
Governing Law. The parties acknowledge and agree that this Note and the rights and obligations of all parties hereunder
shall be governed by and construed under the laws of the State of Delaware, without regard to conflict of laws principles.

17.             
Modification. This Note may not be modified or amended orally, but only by an agreement in writing signed by the party
against whom such agreement is sought to be enforced.

18.             
Entire Agreement. This Note constitutes the entire agreement between the parties with respect to the subject matter hereof
and supersedes any and all prior written or oral agreements and understandings with respect to the matters covered hereby.

Signature
page follows

    	 	6	 

     

    

 

	 	 	CLINIGENCE HOLDINGS, INC.
	 	 	a Delaware corporation
	 	 	 
	 	By:  	 
	 	Its:  	 
	 	Address:  	 

 

    	 	7	 

     

    

EXHIBIT
A

TO

NOTE

NOTICE
OF EXERCISE

To
Be Executed by the Holder

in
Order to Exercise the Note

The
undersigned Holder hereby elects to purchase ________ Conversion Shares pursuant to the attached Note, and requests that certificates
for securities be issued in the name of:

(Please type or print name and address)

 

 

(Social Security or Tax Identification Number)

and
delivered

to:

(Please type or print name and address if different from above)

If
such number of Conversion Shares being purchased hereby shall not be all the Conversion Shares that may be purchased pursuant
to the attached Note, a new Note for the balance of such Shares shall be registered in the name of, and delivered to, the Holder
at the address set forth below.

In
full payment of the purchase price with respect to the Conversion Shares purchased and transfer taxes, if any, the undersigned
hereby tenders payment of $_________ by check, money order or wire transfer payable in United States currency to the order of
[_____________________]

HOLDER:

Dated:
By:/s/

Name: 

Title: 

    	 	8	 

     

    

 

EXHIBIT
B

TO

NOTE

FORM
OF WARRANT

11229\002\8539365.v2EXHIBIT
B

FORM
OF WARRANT

THIS
WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED,
HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE
STATE LAWS, (II) TO THE EXTENT APPLICABLE, RULE 144 UNDER THE ACT (OR ANY SIMILAR RULE UNDER THE ACT RELATING TO THE DISPOSITION
OF SECURITIES), OR (III) AN OPINION OF COUNSEL, IF SUCH OPINION SHALL BE REASONABLY SATISFACTORY TO COUNSEL TO THE ISSUER, THAT
AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE LAW IS AVAILABLE.

STOCK
PURCHASE WARRANT

To
Purchase ___________________ Shares of Common Stock

	No. 2019A-_____	 	 	 	Issue
                                         Date: November 19, 2019

THIS
CERTIFIES that, for value received, _____________ (the “Holder”), is entitled, upon the terms and subject to the conditions
hereinafter set forth, to subscribe for and purchase, from CLINIGENCE HOLDINGS, INC., a Delaware corporation (the “Company”),
of ______________________ (_______) fully paid non-assessable shares of the Company’s common stock, $0.00001 par value per
share (“Common Stock”), at a purchase price of $1.25 per share, provided that such right will terminate, if not terminated
earlier in accordance with the provisions hereof, at 5:00 p.m. (Georgia time) on October 31, 2025 (the “Expiration
Date”).

The
purchase price and the number of shares for which this warrant (the “Warrant”) is exercisable are subject to adjustment,
as provided herein.

This
Warrant was issued in connection with the Company’s private offering (the “Offering”) of investment units of
the Company consisting of a Convertible Promissory in the original principal amount of $5,000 and a warrant to purchase 2,500
shares of Common Stock pursuant to a Confidential Private Offering Memorandum dated October 23, 2019 (the “Memorandum”)
and is subject to the terms of a Subscription Agreement (the “Subscription Agreement”) to which the initial Holder
is a party. Capitalized terms used and not otherwise defined herein will have the respective meanings ascribed to such terms in
the Memorandum.

As
used herein the following terms, unless the context otherwise requires, have the following respective meanings:

(a)              
“Company” means Clinigence Holdings, Inc. and any corporation that shall succeed or assume the obligations of Clinigence
Holdings, Inc. hereunder.

    	 	1	 

     

    

 

(b)              
“Exchange Ratio” has the meaning ascribed to such term in the Merger Agreement.

(c)              
“Exercise Price” shall be $1.25 per Warrant Share, subject to adjustment pursuant to the Merger Agreement or Section
11 hereof.

(d)              
“Merger” means the merger of Merger Sub with and into the Company pursuant to the Merger Agreement, following which
the Company will be a wholly owned subsidiary of Parent.

(e)              
“Merger Agreement” means that certain Agreement and Plan of Merger, dated as of August 8, 2019, by and among the Company,
Parent, HealthDatix, Inc. (“Merger Sub”) and John Salerno.

(f)               
“Parent” means iGambit, Inc., a Delaware corporation.

(g)              
“Warrant Shares” means (i) the Company’s Common Stock and (ii) any Other Securities into which or for which
any of the Common Stock may be converted or exchanged pursuant to a plan of recapitalization, reorganization, merger, sale of
assets or otherwise.

(h)              
“Other Securities” refers to any stock (other than Common Stock) and other securities of the Company or any other
person (corporate or otherwise) which the holder of the Warrant at any time shall be entitled to receive, or shall have received,
on the exercise of the Warrant, in lieu of or in addition to Common Stock, or which at any time shall be issuable or shall have
been issued in exchange for or in replacement of Common Stock or Other Securities. From and after the effective time of the Merger,
the Other Securities shall be shares of common stock of Parent.

This
Warrant, if it is outstanding immediately prior to or issued after the effective time of the Merger, whether or not then vested
or exercisable, shall be, by virtue of the Merger and without any action on the part of the Holder or Parent, be assumed by Parent
and shall be converted into a Parent warrant in accordance with Section 3.3(b) of the Merger Agreement. Each such Parent
warrant as so assumed and converted shall continue to have, and shall be subject to, the same terms and conditions as applied
to this Warrant immediately prior to the effective time of the Merger or, if this Warrant is issued after the effective time of
the Merger, as of the date of issuance. From and after such effective time, each such Parent warrant as so assumed and converted
shall be a warrant to acquire that number of whole shares of Parent common stock (rounded down to the nearest whole share) equal
to the product of: (i) the number of shares of Common Stock subject to this Warrant; and (ii) the Exchange Ratio, at an exercise
price per share of Parent common stock (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (A) $1.25
by (B) the Exchange Ratio.

1.                 
Number of Shares Issuable upon Exercise. Unless sooner terminated in accordance herewith, from and after the date hereof
through and including the Expiration Date, the Holder shall be entitled to receive, upon exercise of this Warrant in whole or
in part, the number of shares of Common Stock of the Company set forth on the first page of this Warrant, subject to adjustment
pursuant hereto, by delivery of an original or fax copy of the exercise notice attached hereto as Exhibit A (the “Notice
of Exercise”), at least 61 days’ prior to the date of exercise, along with payment to the Company of the Exercise
Price. To validly exercise this Warrant, the Notice of Exercise must be received by the Company no later than 61 days before the
Expiration Date.

    	 	2	 

     

    

 

2.                 
Exercise of Warrant.

(a)              
The purchase rights represented by this Warrant are exercisable by the registered Holder hereof, in whole at any time or in part
from time to time by delivery of the Notice of Exercise duly completed and executed at the principal executive office of the Company
(or such other office or agency of the Company as it may designate by notice in writing to the registered Holder hereof at the
address of such Holder appearing on the books of the Company), and upon payment of the Exercise Price of the Warrant Shares thereby
purchased (cash, bank wire transfer, or by certified or official bank check payable to the order of the Company in an amount equal
to the Exercise Price of the shares thereby purchased); whereupon the Holder of this Warrant shall be entitled to receive a certificate
for the number of Warrant Shares so purchased; provided that the Company will place on each certificate a legend substantially
the same as that appearing on this Warrant, in addition to any legend required by any applicable state or federal law. If this
Warrant is exercised in part, the Company will issue to the Holder hereof a new Warrant upon the same terms as this Warrant but
for the balance of Warrant Shares for which this Warrant remains exercisable. The Company agrees that upon proper exercise of
this Warrant the Holder shall be deemed to be the record owner of the shares issued upon such proper exercise as of the close
of business on the date on which this Warrant shall have been exercised as aforesaid (after taking into account, and following
the termination of, any applicable notice period). This Warrant will be surrendered at the time of exercise or if lost, stolen,
misplaced or destroyed, the Holder will comply with Section 7 below. Certificates for shares purchased hereunder shall be delivered
to the Holder hereof within a reasonable time after the date on which this Warrant shall have been exercised as aforesaid.

(b)              
The Company covenants that all Warrant Shares which may be issued upon the exercise of rights represented by this Warrant will,
upon exercise of the rights represented by this Warrant, be fully paid and nonassessable and free from all preemptive rights,
taxes, liens and charges in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue which shall be paid by the Company in accordance with Section 4 below).

3.                 
No Fractional Shares. The Company shall not be required to issue fractional Warrant Shares upon the exercise of this Warrant
or to deliver Warrant Certificates that evidence fractional Warrant Shares. In the event that a fraction of a Warrant Share would,
except for the provisions of this Section 3, be issuable upon the exercise of this Warrant, the Company shall, upon such exercise,
round down to the nearest whole number the number of shares of Common Stock to be issued upon such exercise.

4.                 
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares upon the exercise of this Warrant shall be made
without charge to the Holder hereof for any issue or transfer tax or other incidental expense in respect of the issuance of such
certificate, all of which taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of
the Holder of this Warrant, or in such name or names as may be directed by the Holder of this Warrant; provided, however, that
in the event certificates for Warrant Shares are to be issued in a name other than the name of the Holder of this Warrant, this
Warrant, when exercised, shall be accompanied by the Assignment Form attached hereto as Exhibit B (the “Assignment Form”)
duly executed by the Holder hereof; and provided further, that upon any transfer involved in the issuance or delivery of any certificates
for Warrant Shares, the Company may require, as a condition thereto, that the transferee execute an appropriate investment representation
as may be reasonably required by the Company.

    	 	3	 

     

    

 

5.                 
No Rights as Shareholders. This Warrant does not entitle the Holder hereof to any voting rights or other rights as a stockholder
of the Company prior to the exercise hereof.

6.                 
Exchange and Registry of Warrant. This Warrant is exchangeable, upon the surrender hereof by the registered Holder at the
above mentioned office or agency of the Company, for a new Warrant or Warrants aggregating the total Warrant Shares of the surrendered
Warrant of like tenor and dated as of such exchange. The Company shall maintain at the above mentioned office or agency a registry
showing the name and address of the registered Holder of this Warrant. This Warrant may be surrendered for exchange, transfer
or exercise, in accordance with its terms, at such office or agency of the Company, and the Company shall be entitled to rely
in all respects, prior to written notice to the contrary, upon such registry.

7.                 
Loss; Theft, Destruction or Mutilation of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it
of the loss, theft, destruction or mutilation of this Warrant, and in case of loss, theft or destruction, of indemnity reasonably
satisfactory to it, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and upon surrender and
cancellation of this Warrant, if mutilated, the Company will make and deliver a new Warrant of like tenor (but with no additional
rights or obligations) and dated as of such cancellation, in lieu of this Warrant.

8.                 
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday, then such action may be taken or such
right may be exercised on the next succeeding day not a Saturday, Sunday or legal holiday.

9.                 
Cash Distributions. No adjustment on account of cash dividends or interest on the Company’s Common Stock or Other
Securities that may become purchasable hereunder will be made to the Exercise Price under this Warrant.

10.             
Consolidation, Merger or Sale of the Company. If the Company is a party to a consolidation, merger or transfer of assets
that reclassifies or changes its outstanding Common Stock, the successor corporation (or corporation controlling the successor
corporation or the Company, as the case may be) shall by operation of law assume the Company’s obligations under this Warrant.

    	 	4	 

     

    

 

11.             
Adjustments in the Exercise Price. Subject to the terms of the Merger Agreement, the number of shares and class of capital
stock purchasable under this Warrant are subject to adjustment from time to time as set forth in this Section 11.

(a)              
Adjustment for change in capital stock. If the Company:

(i)                
pays a dividend or makes a distribution on its Common Stock, in each case, in shares of its Common Stock;

(ii)             
subdivides its outstanding shares of Common Stock into a greater number of shares;

(iii)           
combines its outstanding shares of Common Stock into a smaller number of shares;

(iv)            
makes a distribution on its Common Stock in shares of its capital stock other than Common Stock; or

(v)              
issues by reclassification of its shares of Common Stock any shares of its capital stock;

then
the number and classes of shares purchasable upon exercise of each Warrant in effect immediately prior to such action shall be
adjusted so that the holder of any Warrant thereafter exercised may receive the number and classes of shares of capital stock
of the Company which such holder would have owned immediately following such action if such holder had exercised the Warrant immediately
prior to such action.

For
a dividend or distribution the adjustment shall become effective immediately after the record date for the dividend or distribution.
For a subdivision, combination or reclassification, the adjustment shall become effective immediately after the effective date
of the subdivision, combination or reclassification.

If
after an adjustment the Holder, upon exercise of a Warrant, may receive shares of two or more classes of capital stock of the
Company, the Board of Directors of the Company shall in good faith determine the allocation of the adjusted Exercise Price between
or among the classes of capital stock. After such allocation, that portion of the Exercise Price applicable to each share of each
such class of capital stock shall thereafter be subject to adjustment on terms comparable to those applicable to Common Stock
in this Warrant. Notwithstanding the allocation of the Exercise Price between or among shares of capital stock as provided by
this Section 11(a), a Warrant may only be exercised in full by payment of the entire Exercise Price currently in effect.

(b)              
Except as otherwise provided in the Merger Agreement or with respect to any actions taken in connection with or in furtherance
of the Merger, the Company will not, by amendment of its Certificate of Incorporation or through any reorganization, transfer
of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid
the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times
in good faith assist in the carrying out of all the provisions of this Section 11 and in the taking of all such action as may
be necessary or appropriate in order to protect the exercise rights of the Holders of this Warrant against impairment.

    	 	5	 

     

    

 

12.             
Certificate as to Adjustments. In each case (other than as a result of the Merger) of any adjustment or readjustment in
the shares of Common Stock (or Other Securities) issuable on the exercise of the Warrant, the Company at its expense will promptly
cause its Chief Financial Officer or other appropriate designee to compute such adjustment or readjustment in accordance with
the terms of the Warrant and prepare a certificate setting forth such adjustment or readjustment and showing in detail the facts
upon which such adjustment or readjustment is based, including a statement of (a) the consideration received or receivable
by the Company for any additional shares of Common Stock (or Other Securities) issued or sold or deemed to have been issued or
sold, (b) the number of shares of Common Stock (or Other Securities) outstanding or deemed to be outstanding, and (c) the
Exercise Price and the number of shares of Common Stock to be received upon exercise of this Warrant, in effect immediately prior
to such adjustment or readjustment and as adjusted or readjusted as provided in this Warrant. The Company will forthwith mail
a copy of each such certificate to the Holder of the Warrant and any Warrant agent of the Company (appointed pursuant to Section
15 hereof).

13.             
Reservation of Stock Issuable on Exercise of Warrant. The Company will at all times reserve and keep available, solely
for issuance and delivery on the exercise of the Warrant, shares of Common Stock (or Other Securities) from time to time issuable
on the exercise of the Warrant.

14.             
Assignment; Exchange of Warrant. Subject to compliance with applicable securities laws, this Warrant, and the rights evidenced
hereby, may be transferred by any registered Holder hereof (a “Transferor”) with respect to any or all of the shares
underlying this Warrant. On the surrender or exchange of this Warrant, with the Transferor’s duly executed Assignment Form
and together with evidence reasonably satisfactory to the Company demonstrating compliance with applicable securities laws, which
shall include, without limitation, a legal opinion from the Transferor’s counsel that such transfer is exempt from the registration
requirements of applicable securities laws, the Company at its expense (but with payment by the Transferor of any applicable transfer
taxes) will issue and deliver to or on the order of the Transferor thereof a new Warrant of like tenor, in the name of the Transferor
and/or the transferee(s) specified in such Assignment Form (each a “Transferee”), calling in the aggregate on the
face or faces thereof for the number of Warrant Shares called for on the face or faces of the Warrant so surrendered by the Transferor;
and provided further, that upon any such transfer, the Company may require, as a condition thereto, that the Transferee execute
an appropriate investment representation as may be reasonably required by the Company.

15.             
Warrant Agent. The Company may, by written notice to each Holder of a Warrant, appoint an agent for the purpose of issuing
Common Stock (or Other Securities) on the exercise of this Warrant pursuant to Section 2, exchanging this Warrant pursuant to
Section 14, and replacing this Warrant pursuant to Section 7, or any of the foregoing, and thereafter any such issuance,
exchange or replacement, as the case may be, shall be made at such office by such agent.

    	 	6	 

     

    

 

16.             
Notices, etc. All notices shall be in writing signed by the party giving such notice, and delivered personally or sent
by overnight courier or messenger or sent by registered or certified mail (air mail if overseas), return receipt requested, or
by telex, facsimile transmission, telegram or similar means of communication. Notices shall be deemed to have been received on
the date of personal, telex, facsimile transmission, telegram or similar means of communication, or if sent by overnight courier
or messenger, shall be deemed to have been received on the next delivery day after deposit with the courier or messenger, or if
sent by certified or registered mail, return receipt requested, shall be deemed to have been received on the third business day
after the date of mailing. Notices shall be sent to the addresses set forth below each party’s signature on the Subscription
Agreement.

17.             
Notices of Record Date.

In
case, other than in connection with the Merger,

(a)              
The Company takes a record of the holders of its Common Stock for the purpose of entitling them to subscribe for or purchase any
shares of stock of any class or to receive a dividend, distribution or any other rights; or

(b)              
There is any capital reorganization of the Company, reclassification of the capital stock of the Company (other than a subdivision
or combination of its outstanding shares of Common Stock), or consolidation or merger of the Company with or into another corporation
where the Company is not the surviving entity; or

(c)              
There is a voluntary or involuntary dissolution, liquidation or winding up of the Company;

then,
and in any such case, the Company shall cause to be mailed to the Holder, at least 5 business days prior to the date hereinafter
specified, a notice stating the date on which (i) a record is to be taken for the purpose of such dividend, distribution or rights,
or (ii) such reclassification, reorganization, consolidation, merger, dissolution, liquidation or winding up is to take place
and the date, if any is to be fixed, as of which holders of Common Stock of record shall be entitled to exchange their shares
of Common Stock for securities or other property deliverable upon such reclassification, reorganization, consolidation, merger,
dissolution, liquidation or winding up.

18.             
Amendments and Supplements.

(a)              
The Company may from time to time supplement or amend this Warrant without the approval of any Holders in order to cure any ambiguity
or to be correct or supplement any provision contained herein which may be defective or inconsistent with any other provision,
or to make any other provisions in regard to matters or questions herein arising hereunder which the Company may deem necessary
or desirable and which shall not materially adversely affect the interest of the Holder. All other supplements or amendments to
this Warrant must be signed by the party against whom such supplement or amendment is to be enforced.

    	 	7	 

     

    

 

(b)              
Notwithstanding Section 18(a), the Company may at any time during the term of this Warrant reduce the then current Exercise Price
to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.

19.             
Investment Intent. Holder represents and warrants to the Company that Holder is acquiring the Warrant for investment and
with no present intention of distributing or reselling all or any part of the Warrant.

20.             
Certificates to Bear Language. The Warrant Shares issuable upon exercise thereof shall bear the following legend by which
Holder shall be bound:

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT of 1933, AS AMENDED. THE SECURITIES
MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE of SUCH REGISTRATION OR AN OPINION of COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT IS AVAILABLE.”

Certificates
for Warrants or Warrant Shares without such legend shall be issued if such Warrants or Warrant Shares are sold pursuant to an
effective registration statement under the Securities Act of 1933, as amended (the “1933 Act”), or if the Company
has received an opinion from counsel reasonably satisfactory to counsel for the Company, that such legend is no longer required
under the 1933 Act.

21.             
Representations and Warranties of Holder. The Holder hereby represents and warrants that on the date hereof and on each
date of exercise of this Warrant:

(a)              
Securities Not Registered. The Holder is acquiring this Warrant and the Warrant Shares (collectively, the “Securities”)
for its own account, not as an agent or nominee, and not with a view to, or for sale in connection with, any distribution thereof
in violation of applicable securities laws. By accepting this Warrant, the Holder further represents that the Holder does not
have any present contract, undertaking, understanding or arrangement with any person to sell, transfer or grant participations
to such persons or any third person, with respect to any of the Securities.

(b)              
Access to Information. The Company has made available to the Holder the opportunity to ask questions of and to receive
answers from the Company’s officers, directors and other authorized representatives concerning the Company and its business
and prospects, and Holder has been permitted to have access to all information which it has requested in order to evaluate the
merits and risks of the purchase of the Securities.

(c)              
Investment Experience. The Holder is an investor in securities of companies in the development stage and acknowledges that
it is able to fend for itself, can bear the economic risk of its investment, and has such knowledge and experience in financial
and business matters that it is capable of evaluating the merits and risks of the purchase of the Securities.

    	 	8	 

     

    

 

(d)              
Regulation D. The Holder is an “accredited investor” as defined in Rule 501 under the 1933 Act. In the
normal course of business, the Holder invests in or purchases securities similar to the Securities and has such knowledge and
experience in financial and business matters as to be capable of evaluating the merits and risks of purchasing the Securities.
The Holder is not a registered broker dealer or an affiliate of any broker or dealer registered under Section 15(a) of the Exchange
Act of 1934, as amended, or a member of the FINRA or a Person engaged in the business of being a broker dealer.

(e)              
Securities are Unregistered. The Holder has been advised that (i) none of the Securities have been registered under the
1933 Act or other applicable securities laws, (ii) the Securities may need to be held indefinitely, (iii) the Holder will continue
to bear the economic risk of the investment in the Securities after they are subsequently registered under the 1933 Act or an
exemption from such registration is available, and (iv) when and if the Securities may be disposed of without registration in
reliance on Rule 144 promulgated under the 1933 Act, such disposition may be made only in amounts in accordance with the terms
and conditions of such Rule in effect at that time.

(f)               
Pre-Existing Relationship. The Holder has a pre-existing personal or business relationship with the Company or any of its
officers, directors or controlling persons, or by his/its business or financial experience or the business or financial experience
of his/its financial advisors who are unaffiliated with and who are not compensated by the Company, directly or indirectly, could
be reasonably assumed to have the capacity to protect his/its own interest in connection with the acquisition of the Securities.

(g)              
No Advertisement. The Holder acknowledges that the offer and sale of the Securities was not accomplished by the publication
of any advertisement.

(h)              
No Review. The Holder understands that no arbitration board or panel, court or federal, state, municipal or other governmental
department, commission, board, bureau, agency or instrumentality, domestic or foreign, has passed upon or made any recommendation
or endorsement of the common stock into which it converts.

(i)                
Legal Representation. The Holder has had the opportunity to confer with legal counsel of its choosing regarding the issuance
of the Securities and any related transactions.

22.             
Survival of Representation and Warranties. All representations and warranties made by the Holder shall survive the earlier
of the Expiration Date and shall remain effective and enforceable until the earlier to occur of the Expiration Date or the date
on which claims based thereon shall have been barred by the applicable statutes of limitation.

23.             
Miscellaneous.

(a)              
This Warrant shall be governed by and construed in accordance with the laws of the State of Delaware without regard to principles
of conflicts of laws. The parties submit to the jurisdiction of the Courts of the County of Fulton, State of Georgia or a Federal
Court empaneled in the State of Georgia for the resolution of all legal disputes arising under the terms of this Warrant, including,
but not limited to, enforcement of any arbitration award. The Company and the Holder agree to submit to the jurisdiction of such
courts and waive trial by jury.

    	 	9	 

     

    

 

(b)              
If any action or proceeding is brought by the Company on the one hand or by the Holder on the other hand to enforce or continue
any provision of this Warrant, the prevailing party’s costs and expenses, including its reasonable attorney’s fees,
in connection with such action or proceeding shall be paid by the other party.

(c)              
In the event that any provision of this Warrant is invalid or unenforceable under any applicable statute or rule of law, then
such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any such provision, which may prove invalid or unenforceable under any law, shall not affect
the validity or enforceability of any other provision of this Warrant.

(d)              
The headings in this Warrant are for purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

    	 	10	 

     

    

 

IN WITNESS WHEREOF, the Company has
caused this Warrant to be executed by its officer thereunto duly authorized as of the date first written above.

 

	 	 	CLINIGENCE HOLDINGS, INC.
	 	 	a Delaware corporation
	 	 	 
	 	By:  	 
	 	 	Jacob Margolin
	 	 	Chief Executive Officer

 

    	 	11	 

     

    

 

EXHIBIT
A

TO

WARRANT

NOTICE
OF EXERCISE

(To
Be Executed by the Holder in Order to Exercise the Warrant)

The
undersigned Holder hereby elects to purchase ________ Shares pursuant to the attached Warrant, and requests that certificates
for securities be issued in the name of :

(Please type or print name and address)

 

 

(Social Security or Tax Identification Number)

and
delivered

to:
                                

(Please type or print name and address if different from above)

If
such number of Shares being purchased hereby shall not be all the Shares that may be purchased pursuant to the attached Warrant,
a new Warrant for the balance of such Shares shall be registered in the name of , and delivered to, the Holder at the address
set forth below.

In
full payment of the purchase price with respect to the Shares purchased and transfer taxes, if any, the undersigned hereby tenders
payment of $_________ by check, money order or wire transfer payable in United States currency to the order of [_____________________]

HOLDER:

Dated:
By:                               

Name:                                  

Title:                                    

    	 	12	 

     

    

 

EXHIBIT
B

TO

WARRANT

FORM
OF ASSIGNMENT

(To
be signed only on transfer of Warrant)

For
value received, the undersigned hereby sells, assigns, and transfers unto _________________ the right represented by the within
Warrant to purchase _______ shares of Common Stock of Clinigence Holdings, Inc., a Delaware corporation, to which the within Warrant
relates, and appoints ______________________ Attorney to transfer such right on the books of Clinigence Holdings, Inc., a Delaware
corporation, with full power of substitution of premises.

Dated:
By:                             

Name:                           

Title:                            

 
 (signature must conform to name of holder as specified
on the fact of the Warrant)

Address:

Signed
in the presence of :

Dated:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]